



Innovative Cell and Tissue Technology

Pressrelease
February 10, 2009
Göteborg, Sweden

Vitrolife announces new date for report on operations

Due to the public voluntary offer by Vitrolife for MediCult a/s, the Board of Directors of Vitrolife has decided to release the report on operations for 2008 on February 12, in order to give the recipients of the voluntary offer more time and a better chance to evaluate the offer in full.

In connection with the publication of the report on operations for 2008 Vitrolife will hold a telephone conference with CEO Magnus Nilsson.

Time: Thursday, February 12, 2009 at 2 p.m. CET.

Telephone number: +46 8 505 201 10

Conference name: Vitrolife

Before the conference call, slides will be available on the company website, www.vitrolife.com, under the section Investors/News.

A recorded version of the presentation will be available for seven days on telephone number +46 8 505 203 33, access code 825821.

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and its products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

Vitrolife is required under the Swedish Securities Market Act to publish the information in this press release. The information was submitted for publication on 10 February 2009 at 3.30 pm CET.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.